Jasper Therapeutics Business Summary

Jasper Therapeutics, Inc. (JSPR) is a clinical-stage biotechnology company that generates revenue primarily through strategic collaboration agreements, government grants, and public equity offerings, as it currently has no commercialized products. The company’s business model is centered on the clinical development of its lead asset, briquilimab (formerly JSP191), a targeted aglycosylated monoclonal antibody that blocks the KIT (CD117) receptor to deplete mast cells and diseased stem cells. Its primary business segments are focused on chronic mast cell-driven diseases, specifically chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma, following a 2025 strategic pivot away from its original stem cell conditioning focus. Jasper competes directly with Celldex Therapeutics (barzolvolimab), Novartis (remibrutinib), and Eledon Pharmaceuticals, positioning itself in the market as a developer of a potentially safer, more targeted alternative to traditional immunosuppressants and systemic therapies for chronic inflammatory conditions. The company was co-founded by Dr. Judith Shizuru, a professor at Stanford University and a pioneer in blood and marrow transplantation, and Dr. Susan Prohaska, an expert in stem cell biology. As of February 2026, the executive leadership team is headed by President and CEO Jeet Mahal, who assumed the role in January 2026 after serving as the company’s COO and CFO; he brings over 30 years of industry experience from Portola Pharmaceuticals and Johnson & Johnson. Thomas Wiggans, the former CEO of Dermira, serves as Executive Chairperson, providing veteran oversight alongside CFO Herbert Cross and Acting Chief Medical Officer Daniel Adelman. Jasper’s growth is supported by a notable investor base including Roche Venture Fund, Abingworth, and Qiming Venture Partners, with a board of directors that integrates deep academic pedigree from Stanford with commercial expertise to navigate upcoming registrational programs.